ABSTRACT
Chloramphenicol, a broad-spectrum antibiotic employed for controlling bacterial infections, presents an intriguing aspect in terms of its environmental fate in soils. 14C-labeled chloramphenicol was used to explore its mineralization and residue characteristics in three distinct agricultural soils in China. The findings revealed a nuanced pattern in the fate of 14C-chloramphenicol, with notable variations among the different soils under investigation. The chloramphenicol extract residue exhibited a reduction of 18.04% in sandy clay soil, 23.04% in clay loam soil, and 21.73% in loamy clay soil. Notably, the mineralization rate in sandy clay soil was 25.22% surpassed that in the other two soils, particularly during the initial stages of incubation. Over time, the diminishing extract residue underwent conversion into minerals and bound residue. The formation rate of bound residue was increased from 44.59 to 53.65% after adding 10% manure, suggesting that chloramphenicol easily binds with soils rich in organic matter. The bound residue is predominantly localized in the humin fraction across all soils. Additionally, the sterilized soil experiments indicated the pivotal role of microorganisms in influencing the fate of chloramphenicol under the specified experimental conditions. In conclusion, this study offers valuable insights into the environmental dynamics of chloramphenicol in soils, emphasizing the importance of soil composition, organic matter content, and microbial activity. The findings contribute to a scientific understanding of the environmental safety implications associated with chloramphenicol usage.
Subject(s)
Chloramphenicol , Soil , Soil/chemistry , Carbon Radioisotopes , Clay , Sand , Plant Extracts , CarbonABSTRACT
Graphite sheet (GS) electrodes are flexible and versatile substrates for sensing electrochemical; however, their use has been limited to incorporate (bio)chemical modifiers. Herein, we demonstrated that a cold (low temperature) CO2 plasma treatment of GS electrodes provides a substantial improvement of the electrochemical activity of these electrodes due to the increased structural defects on the GS surface as revealed by Raman spectroscopy (ID/IG ratio), and scanning electron microscopy images. XPS analyses confirmed the formation of oxygenated functional groups at the GS surface after the plasma treatment that are intrinsically related to the substantial increase in the electron transfer coefficient (K0 values increased from 1.46 × 10-6 to 2.09 × 10-3 cm s-1) and with reduction of the resistance to charge transfer (from 129.8 to 0.251 kΩ). The improved electrochemical activity of CO2-GS electrodes was checked for the detection of emerging contaminant species, such as chloramphenicol (CHL), ciprofloxacin (CIP) and sulphanilamide (SUL) antibiotics, at around + 0.15, + 1.10 and + 0.85 V (versus Ag/AgCl), respectively, by square wave voltammetry. Limit of detection values in the submicromolar range were achieved for CHL (0.08 µmol L-1), CIP (0.01 µmol L-1) and SFL (0.11 µmol L-1), which enabled the sensor to be successfully applied to natural waters and urine samples (recovery values from 85 to 119%). The CO2-GS electrode is highly stable and inexpensive ($0.09 each sensor) and can be easily inserted in portable 3D printed cells for environmental on-site analyses.
Subject(s)
Chloramphenicol , Graphite , Ciprofloxacin , Sulfanilamide , Carbon Dioxide , ElectrodesABSTRACT
The continuous emergence of bacterial resistance alters the activities of different antibiotic families and requires appropriate strategies to solve therapeutic impasses. Medicinal plants are an attractive source for researching alternative and original therapeutic molecules. In this study, the fractionation of natural extracts from A. senegal and the determination of antibacterial activities are associated with molecular networking and tandem mass spectrometry (MS/MS) data used to characterize active molecule(s). The activities of the combinations, which included various fractions plus an antibiotic, were investigated using the "chessboard" test. Bio-guided fractionation allowed the authors to obtain individually active or synergistic fractions with chloramphenicol activity. An LC-MS/MS analysis of the fraction of interest and molecular array reorganization showed that most identified compounds are Budmunchiamines (macrocyclic alkaloids). This study describes an interesting source of bioactive secondary metabolites structurally related to Budmunchiamines that are able to rejuvenate a significant chloramphenicol activity in strains that produce an AcrB efflux pump. They will pave the way for researching new active molecules for restoring the activity of antibiotics that are substrates of efflux pumps in enterobacterial-resistant strains.
Subject(s)
Acacia , Escherichia coli Proteins , Humans , Escherichia coli/metabolism , Tandem Mass Spectrometry , Chromatography, Liquid , Senegal , Anti-Bacterial Agents/chemistry , Chloramphenicol/pharmacology , Chloramphenicol/metabolism , Microbial Sensitivity Tests , Multidrug Resistance-Associated Proteins/metabolism , Escherichia coli Proteins/metabolismABSTRACT
Various antibiotics are available, including gentamicin, chloramphenicol, ampicillin, amoxicillin, and streptomycin, but they have some restrictions. Many microorganisms are resistant to these medications. A new antimicrobial source must be found or developed to solve this issue. Inhere, extract from seaweeds Ulva lactuca was investigated for its antibacterial activity using a well diffusion assay against Klebsiella pneumoniae, and a promising inhibition zone diameter was recorded to be 14.04 mm. The biochemical structure of the antibacterial compound was determined via GC-MS and FTIR analysis. Also, a micro-dilution assay was used to calculate the minimum concentration that makes inhibition (MIC) to be 1.25 mg/ml from U. extract reliable to prevent the visibility of any bacterial growth, this was followed by examining the antibacterial effect of U. Lactuca methanolic extract alone and the synergetic effect of U. Lactuca methanolic extract in combination with two different antibiotics (gentamicin and chloramphenicol). This was assayed by the agar well diffusion method to achieve promising and strong inhibiting power against K. pneumoniae. It was deduced that the maximum synergism could be achieved by adding 2.5 mg/ml of Ulva methanolic extract to gentamicin (4 µg/ml), and the results were illustrated obviously via transmission electron microscope in which severe morphological deteriorations were experienced by the treated cells. From this study, we can conclude that U. lactucae extract has the power to aid antibiotics in reducing the growth of pathogenic K. pneumoniae.
Subject(s)
Anti-Bacterial Agents , Ulva , Anti-Bacterial Agents/chemistry , Ulva/chemistry , Klebsiella pneumoniae , Methanol , Microbial Sensitivity Tests , Chloramphenicol/pharmacology , Gentamicins/pharmacology , Plant Extracts/pharmacology , Plant Extracts/chemistryABSTRACT
Multiresponsive hydrogels, which are smart soft materials that respond to more than one external stimulus, have emerged as powerful tools for biomedical applications, such as drug delivery. Within this context and with the aim of eliminating the systematic administration of antibiotics, special attention is being paid to the development of systems for controlled delivery of antibiotic for topical treatment of bacterial infections. In this work, an electro-chemo responsive hydrogel able to release chloramphenicol (CAM), a broad spectrum antibiotic also used for anticancer therapy, is proposed. This has been prepared by grafting poly(acrylic acid) (PAA) to sodium alginate (Alg) and in situ encapsulation of poly(3,4-ethylenedioxythiophene) nanoparticles loaded with CAM (PEDOT/CAM NPs), which were obtained by emulsion polymerization. Although the response to electrical stimuli of PEDOT was the main control for the release of CAM from PEDOT/CAM NPs, the release by passive diffusion had a relatively important contribution. Conversely, the passive release of antibiotic from the whole engineered hydrogel system, Alg-g-PAA/PEDOT/CAM, was negligible, whereas significant release was achieved under electrostimulation in an acid environment. Bacterial tests and assays with cancer cells demonstrated that the biological activity of CAM remained after release by electrical stimulation. Notably, the successful dual-response of the developed hydrogel to electrical stimuli and pH changes evidence the great prospect of this smart material in the biomedical field, as a tool to fight against bacterial infections and to provide local cancer treatment.
Subject(s)
Bacterial Infections , Chloramphenicol , Humans , Hydrogels , Anti-Bacterial Agents , Hydrogen-Ion ConcentrationABSTRACT
BACKGROUND: Typhoid and paratyphoid (enteric fever) are febrile bacterial illnesses common in many low- and middle-income countries. The World Health Organization (WHO) currently recommends treatment with azithromycin, ciprofloxacin, or ceftriaxone due to widespread resistance to older, first-line antimicrobials. Resistance patterns vary in different locations and are changing over time. Fluoroquinolone resistance in South Asia often precludes the use of ciprofloxacin. Extensively drug-resistant strains of enteric fever have emerged in Pakistan. In some areas of the world, susceptibility to old first-line antimicrobials, such as chloramphenicol, has re-appeared. A Cochrane Review of the use of fluoroquinolones and azithromycin in the treatment of enteric fever has previously been undertaken, but the use of cephalosporins has not been systematically investigated and the optimal choice of drug and duration of treatment are uncertain. OBJECTIVES: To evaluate the effectiveness of cephalosporins for treating enteric fever in children and adults compared to other antimicrobials. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, the WHO ICTRP and ClinicalTrials.gov up to 24 November 2021. We also searched reference lists of included trials, contacted researchers working in the field, and contacted relevant organizations. SELECTION CRITERIA: We included randomized controlled trials (RCTs) in adults and children with enteric fever that compared a cephalosporin to another antimicrobial, a different cephalosporin, or a different treatment duration of the intervention cephalosporin. Enteric fever was diagnosed on the basis of blood culture, bone marrow culture, or molecular tests. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were clinical failure, microbiological failure and relapse. Our secondary outcomes were time to defervescence, duration of hospital admission, convalescent faecal carriage, and adverse effects. We used the GRADE approach to assess certainty of evidence for each outcome. MAIN RESULTS: We included 27 RCTs with 2231 total participants published between 1986 and 2016 across Africa, Asia, Europe, the Middle East and the Caribbean, with comparisons between cephalosporins and other antimicrobials used for the treatment of enteric fever in children and adults. The main comparisons are between antimicrobials in most common clinical use, namely cephalosporins compared to a fluoroquinolone and cephalosporins compared to azithromycin. Cephalosporin (cefixime) versus fluoroquinolones Clinical failure, microbiological failure and relapse may be increased in patients treated with cefixime compared to fluoroquinolones in three small trials published over 14 years ago: clinical failure (risk ratio (RR) 13.39, 95% confidence interval (CI) 3.24 to 55.39; 2 trials, 240 participants; low-certainty evidence); microbiological failure (RR 4.07, 95% CI 0.46 to 36.41; 2 trials, 240 participants; low-certainty evidence); relapse (RR 4.45, 95% CI 1.11 to 17.84; 2 trials, 220 participants; low-certainty evidence). Time to defervescence in participants treated with cefixime may be longer compared to participants treated with fluoroquinolones (mean difference (MD) 1.74 days, 95% CI 0.50 to 2.98, 3 trials, 425 participants; low-certainty evidence). Cephalosporin (ceftriaxone) versus azithromycin Ceftriaxone may result in a decrease in clinical failure compared to azithromycin, and it is unclear whether ceftriaxone has an effect on microbiological failure compared to azithromycin in two small trials published over 18 years ago and in one more recent trial, all conducted in participants under 18 years of age: clinical failure (RR 0.42, 95% CI 0.11 to 1.57; 3 trials, 196 participants; low-certainty evidence); microbiological failure (RR 1.95, 95% CI 0.36 to 10.64, 3 trials, 196 participants; very low-certainty evidence). It is unclear whether ceftriaxone increases or decreases relapse compared to azithromycin (RR 10.05, 95% CI 1.93 to 52.38; 3 trials, 185 participants; very low-certainty evidence). Time to defervescence in participants treated with ceftriaxone may be shorter compared to participants treated with azithromycin (mean difference of -0.52 days, 95% CI -0.91 to -0.12; 3 trials, 196 participants; low-certainty evidence). Cephalosporin (ceftriaxone) versus fluoroquinolones It is unclear whether ceftriaxone has an effect on clinical failure, microbiological failure, relapse, and time to defervescence compared to fluoroquinolones in three trials published over 28 years ago and two more recent trials: clinical failure (RR 3.77, 95% CI 0.72 to 19.81; 4 trials, 359 participants; very low-certainty evidence); microbiological failure (RR 1.65, 95% CI 0.40 to 6.83; 3 trials, 316 participants; very low-certainty evidence); relapse (RR 0.95, 95% CI 0.31 to 2.92; 3 trials, 297 participants; very low-certainty evidence) and time to defervescence (MD 2.73 days, 95% CI -0.37 to 5.84; 3 trials, 285 participants; very low-certainty evidence). It is unclear whether ceftriaxone decreases convalescent faecal carriage compared to the fluoroquinolone gatifloxacin (RR 0.18, 95% CI 0.01 to 3.72; 1 trial, 73 participants; very low-certainty evidence) and length of hospital stay may be longer in participants treated with ceftriaxone compared to participants treated with the fluoroquinolone ofloxacin (mean of 12 days (range 7 to 23 days) in the ceftriaxone group compared to a mean of 9 days (range 6 to 13 days) in the ofloxacin group; 1 trial, 47 participants; low-certainty evidence). AUTHORS' CONCLUSIONS: Based on very low- to low-certainty evidence, ceftriaxone is an effective treatment for adults and children with enteric fever, with few adverse effects. Trials suggest that there may be no difference in the performance of ceftriaxone compared with azithromycin, fluoroquinolones, or chloramphenicol. Cefixime can also be used for treatment of enteric fever but may not perform as well as fluoroquinolones. We are unable to draw firm general conclusions on comparative contemporary effectiveness given that most trials were small and conducted over 20 years previously. Clinicians need to take into account current, local resistance patterns in addition to route of administration when choosing an antimicrobial.
Subject(s)
Anti-Infective Agents , Paratyphoid Fever , Typhoid Fever , Child , Adult , Humans , Adolescent , Paratyphoid Fever/drug therapy , Typhoid Fever/drug therapy , Cephalosporins/therapeutic use , Azithromycin/adverse effects , Ceftriaxone/therapeutic use , Cefixime/therapeutic use , Fluoroquinolones/therapeutic use , Anti-Bacterial Agents/therapeutic use , Chloramphenicol/therapeutic use , Anti-Infective Agents/therapeutic use , Monobactams/therapeutic use , Ciprofloxacin/therapeutic use , Ofloxacin/therapeutic use , Recurrence , PakistanABSTRACT
The characteristics of growth and injury of Bacillus subtilis spores whose heat resistance was reduced by the treatment of high hydrostatic pressure processing (HPP) combined with/without alkaline electrolyzed water (AlEW) were investigated. The delay in the lag phase of growth curve observed when used in combination with AlEW, especially at 50 MPa or less, and was prolonged by about 4 to 6 hours. However, the effects of temperature and time during treatment on the lag phase were not significantly different between solo-HPP and in combination with AlEW. The injury characteristics of the treated bacterial spores were evaluated by using antibiotics (penicillin G, rifampicin and chloramphenicol) supplemented trypticase soy broth. In the chloramphenicol supplemented TSB, although the lag phase of bacterial spores treated by HPP with AlEW was not prolonged as compared with the normal-TSB, the decrease in growth rate during logarithmic phase and increase in maximum growth amount were observed. This result could suggest due to a damage by combined treatment of HPP with AlEW such as the inhibition of protein synthesis. Furthermore, the combined treatment with AlEW increased the catalase activity by 1.45, 1.63 and 4.25 times at 30, 80 and 100 MPa, respectively, as compared with solo-HPP, therefore the combined treatment could cause high oxidative stress on bacterial spores.
Subject(s)
Rifampin , Spores, Bacterial , Anti-Bacterial Agents/pharmacology , Catalase , Chloramphenicol/pharmacology , Hot Temperature , Hydrostatic Pressure , Rifampin/pharmacology , WaterABSTRACT
BACKGROUND: Fusarium species are saprophytic fungi with a worldwide distribution. These fungi cause various infections among immunocompromised patients; however, they can also involve immunocompetent individuals. CASE PRESENTATION: We report a case of a 41-year-old Iranian woman who presented with ulcerative lesions on her lips 10 months ago. She had a long history of anxiety but had no history of classical risk factors such as trauma, cosmetic lip tattoo, burning in her lips, smoking or use of alcohol and opium. A skin biopsy from the lower lip was performed and sent for microbiological examinations. Hyaline septate hyphae were seen on direct microscopy with potassium hydroxide. The clinical specimen was subcultured on sabouraud dextrose agar with chloramphenicol and prepared for antifungal susceptibility testing and molecular identification. Considering the minimum inhibitory concentrations (MIC) for antifungals, itraconazole (100 mg orally twice a day) was started for her, and after 2 months, the lesions were treated. She followed up for 3 months, and no signs of disease recurrence were observed. CONCLUSIONS: Selecting an appropriate treatment strategy according to the laboratory assessments is essential in clinical practice and the management of rare infections to prevent related mortality and morbidity of opportunistic fungal infections.
Subject(s)
Fusarium , Itraconazole , Adult , Agar , Antifungal Agents/therapeutic use , Chloramphenicol , Female , Glucose , Humans , Iran , Itraconazole/therapeutic use , Lip , Opium , Ulcer/drug therapyABSTRACT
Background: To explore the efficacy and safety of drugs in patients with scrub typhus. Methods: For this systematic review and network meta-analysis, we searched PubMed, Embase, Web of Science, Cochrane Central Register of Clinical Trials, China National Knowledge Infrastructure (CNKI), and Wanfang data (WF) up to December 2021. All randomized controlled trials (RCTs) of antibiotics used to treat scrub typhus were included without language or date restrictions. The overall effectiveness was evaluated from 4 perspectives: cure rate (CR), defervescence time (DT), gastrointestinal symptoms-adverse events (GS-AD), and abnormal blood count-adverse events (ABC-AD). The quality of evidence was evaluated using the Cochrane Risk of Bias tool and GRADE system. Results: Sixteen studies involving 1,582 patients were included to evaluate 7 drugs, namely, azithromycin, doxycycline, chloramphenicol, tetracycline, rifampin, moxifloxacin, and telithromycin. In this network meta-analysis, rifampicin (82%) and chloramphenicol (65%) were more effective in terms of CR, and moxifloxacin (3%) from the quinolone family was the worst. Azithromycin caused the fewest events in terms of ABC-AD. No differences were found in this network meta-analysis (NMA) in terms of DT and GS-AD. Conclusions: Rifampicin was associated with the highest CR benefit and the lowest risk of DT when used to treat patients with scrub typhus, except in areas where tuberculosis (TB) was endemic. Azithromycin was found to be better in CR and was associated with a lower probability of GS-AD and ABC-AD; therefore, it may be considered to treat pregnant women and children. Moxifloxacin had a much lower CR than other drugs and is, therefore, not recommended for the management of scrub typhus. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42021287837.
Subject(s)
Scrub Typhus , Anti-Bacterial Agents/therapeutic use , Azithromycin/adverse effects , Child , Chloramphenicol/therapeutic use , Female , Humans , Moxifloxacin/therapeutic use , Network Meta-Analysis , Rifampin/therapeutic use , Scrub Typhus/drug therapy , Scrub Typhus/epidemiologyABSTRACT
Brucellosis is among the most prevalent zoonotic infections in Middle Eastern and North African (MENA) countries, critically impacting human and animal health. A comprehensive review of studies on antibiotic susceptibility and therapeutic regimes for brucellosis in ruminants and humans in the MENA region was conducted to evaluate the current therapeutic management in this region. Different scientific databases were searched for peer-reviewed original English articles published from January 1989 to February 2021. Reports from research organizations and health authorities have been taken into consideration. Brucella melitensis and Brucella abortus have been reported from the majority of MENA countries, suggesting a massive prevalence particularly of B. melitensis across these countries. Several sporadic cases of brucellosis relapse, therapeutic failure, and antibiotic resistance of animal and human isolates have been reported from the MENA region. However, several studies proved that brucellae are still in-vitro susceptible to the majority of antibiotic compounds and combinations in current recommended World Health Organization (WHO) treatment regimens, for example, levofloxacin, tetracyclines, doxycycline, streptomycin, ciprofloxacin, chloramphenicol, gentamicin, tigecycline, and trimethoprim/sulfamethoxazole. The current review presents an overview on resistance development of brucellae and highlights the current knowledge on effective antibiotics regimens for treating human brucellosis.
Subject(s)
Brucella melitensis , Brucellosis , Animals , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Brucellosis/drug therapy , Brucellosis/epidemiology , Brucellosis/veterinary , Chloramphenicol/therapeutic use , Ciprofloxacin/therapeutic use , Doxycycline , Gentamicins/therapeutic use , Humans , Levofloxacin/therapeutic use , Microbial Sensitivity Tests/veterinary , Middle East/epidemiology , Ruminants , Streptomycin/therapeutic use , Tigecycline/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic useABSTRACT
To determinate the antimicrobial effect of chloramphenicol and aqueous extract against multidrug-resistant enterohemorrhagic Escherichia coli (EHEC) and Salmonella enterica serovar Typhimurium in CD-1 mice. Aqueous extract was isolated from Hibiscus sabdariffa calyces. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of chloramphenicol and aqueous extract were determined for EHEC and S. Typhimurium. Nine groups of six mice each were formed. Three groups were inoculated orally with 1 × 104 colony-forming units (CFU) of S. Typhimurium, three groups were inoculated with 1 × 104 CFU of EHEC and the remaining three groups were not inoculated. Six hours postinoculation, the mice of some groups were orally administered solutions of aqueous extract (50 mg/mL), chloramphenicol (82 µg/mL), or isotonic saline. The EHEC and S. Typhimurium concentration in all mice feces was determined. For both pathogens, the MIC and MBC values of aqueous extract were 20 y 50 mg/mL, respectively; for chloramphenicol, they were between 17.5 and 82 µg/mL. EHEC and S. Typhimurium were not detected in the feces of mice that were administered aqueous extract on the 2nd and 3rd days posttreatment. Furthermore, these mice recovered from the infection. In contrast, in mice not treated, or treated with chloramphenicol alone, pathogens were isolated from their feces throughout the study, and some mice died. The H. sabdariffa calyx extracts could be an alternative to control multidrug-resistant bacteria in humans and animals.
Subject(s)
Anti-Infective Agents , Enterohemorrhagic Escherichia coli , Hibiscus , Animals , Anti-Infective Agents/pharmacology , Chloramphenicol/pharmacology , Humans , Mice , Plant Extracts/pharmacology , Salmonella typhimurium , WaterABSTRACT
An immunobiosensor assay was developed for multi-residue screening in bovine milk of the parent amphenicols, thiamphenicol and florfenicol, along with the metabolite florfenicol amine. A polyclonal antibody raised in a rabbit after immunisation with a florfenicol amine-protein conjugate was employed in the assay. Milk samples were subjected to acetonitrile extraction, reconstituted in buffer and diluted prior to biosensor analysis. Validation data obtained from the analysis of fortified samples has shown that the method has a detection capability of less than 0.25 µg kg-1 for florfenicol and less than 0.5 µg kg-1 for florfenicol amine and thiamphenicol. The cross-reactivity profile and validation data for the detection of these amphenicols is presented together with results obtained following the analysis of florfenicol incurred samples using the developed screening method along with a comparison of results obtained from the analysis of the same incurred samples using an MRM3 UPLC-MS/MS confirmatory method. Results are also presented obtained from the analysis of samples from both treated and non-treated animals which were co-housed and which show the potential for cross-contamination.
Subject(s)
Anti-Bacterial Agents/analysis , Chloramphenicol/analysis , Drug Residues/analysis , Milk/chemistry , Animals , Biosensing Techniques , Cattle , Chromatography, High Pressure Liquid , Drug Evaluation, Preclinical , Food Hypersensitivity , Humans , Tandem Mass Spectrometry , Thiamphenicol/analogs & derivatives , Thiamphenicol/analysisABSTRACT
Bacteriophage therapy is acknowledged as a potential tool to prevent or treat multidrug-resistant bacterial infections. In this study, our major focus was on the bacteriolytic activity of phage EcSw (ΦEcSw) against the emergence of the clinically important Escherichia coli Sw1 and E. coli O157:H7. The amount of the antibiotics was changed in a concentration-dependent manner, and the ΦEcSw susceptibility to antibiotics was determined. The kanamycin and chloramphenicol inhibited the titre of phage, but ampicillin did not show phage inhibition. Though the kanamycin and chloramphenicol controlled the growth of Sw1 in a concentration-dependent manner, the ampicillin did not due to the resistance. The combined activity of the ΦEcSw with antibiotics (kanamycin and chloramphenicol) compared with the antibiotics alone showed significant lytic activity p < .001). In addition, phage-based therapy was evaluated for controlling the multidrug-resistant E. coli Sw1 and E. coli O157:H7 in zebrafish and BALB/c mice, respectively. Our results provide novel advantages of phage therapy and phage-antibiotic therapy to control antibiotic-resistant bacteria.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Resistance, Multiple, Bacterial/drug effects , Escherichia coli Infections/drug therapy , Escherichia coli O157/drug effects , Phage Therapy/veterinary , Rodent Diseases/drug therapy , Ampicillin/therapeutic use , Animals , Bacteriophages/physiology , Chloramphenicol/therapeutic use , Combined Modality Therapy , Escherichia coli Infections/veterinary , Kanamycin/therapeutic use , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Microbial Viability/drug effects , ZebrafishABSTRACT
OBJECTIVE: to compare the healing by second intention under the effects of topical application of honey, copaíba oil-resin and a commercial product (fibrinolysin, deoxyribonuclease and chloramphenicol) with a control group in rats. METHODS: we carried out a skin resection, 1cm in diameter, on the back of 40 rats allocated to four groups of ten animals. All wounds were cleaned daily with 2ml of 0.9% NaCl solution. The first group (control - GC) was restricted to such procedure. In the wounds of the second (GM), third (GO) and fourth groups (GF), after cleaning, we respectively applied 1ml of honey, 1ml of copaíba oil-resin and 1ml of cream containing fibrinolysin, deoxyribonuclease and chloramphenicol. The wounds were occluded with sterile gauze. Immediately after the incision and on days three, seven and 14 of the experiment, the wounds were copied and contraction was analyzed using planimetry. After euthanasia, we histologically evaluated the inflammatory reaction and collagen in the scars. RESULTS: the reduction of the wound area of GM (p=0.003), GO (p=0.011) and GF (p=0.002) were higher than the GC. The amount of type-I collagen present in GM and GO was higher than in GC and GF groups (p<0.05). There was a predominance of chronic inflammatory stage in GM (p=0.004), GO (p<0.001) and GF (p=0.003) when compared with GC. CONCLUSION: the topical use of honey and copaíba oil-resin increases wound contraction, the presence of type-I collagen and accelerates healing.
OBJETIVO: comparar a cicatrização, por segunda intenção, sob os efeitos da aplicação tópica de mel, óleo-resina de copaíba e um produto comercial (fibrinolisina, desoxirribonuclease e cloranfenicol) a um grupo controle, em ratos. MÉTODOS: ressecção de pele, com 1cm de diâmetro, foi realizada no dorso de 40 ratos alocados em quatro grupos de dez animais. Todas as feridas foram limpas, diariamente, com 2ml de solução de NaCl 0,9%. O primeiro grupo (controle - GC) ficou restrito a tal procedimento. Nas feridas do segundo (GM), terceiro (GO) e quarto grupos (GF), após limpeza, aplicou-se, respectivamente, 1ml de mel, 1ml de óleo-resina de copaíba e 1ml de creme contendo fibrinolisina, desoxirribonuclease e cloranfenicol. Ocluíram-se as feridas com gaze estéril. Imediatamente após a incisão e nos dias três, sete e 14 do experimento, as feridas foram copiadas e, usando planimetria, analisou-se a contração. Após a eutanásia, a histologia foi utilizada para avaliação da reação inflamatória e do colágeno nas cicatrizes. RESULTADOS: a redução da área da ferida do GM (p=0,003), GO (p=0,011) e GF (p=0,002) foram superiores ao do GC. A quantidade de colágeno tipo I presente no GM e no GO foi superior aos grupos GC e GF (p<0,05). Houve predominância do estágio inflamatório crônico no GM (p=0,004), GO (p<0,001) e GF (p=0,003) quando comparados ao GC. CONCLUSÃO: o uso tópico do mel e do óleo-resina de copaíba aumenta a contração da ferida, a presença de colágeno tipo I e acelera a cicatrização.
Subject(s)
Anti-Infective Agents/administration & dosage , Fabaceae/chemistry , Honey , Plant Extracts/administration & dosage , Plant Oils/administration & dosage , Wound Healing/drug effects , Administration, Topical , Animals , Chloramphenicol/administration & dosage , Deoxyribonuclease I/administration & dosage , Disease Models, Animal , Fibrinolysin/administration & dosage , Male , Rats , Rats, WistarABSTRACT
Nanozymes have gained increasing attention in the field of biosensing. Rationally designed nanozymes with excellent catalytic activity are accessible to substitute natural enzymes. Herein, a novel self-powered photoelectrochemical (PEC) aptasensor was constructed for ultrasensitive detection of chloramphenicol (CAP) based on ultrathin PtNi nanowires (NWs) as nanozyme and benzene-ring doped g-C3N4 (BR-CN) as the photoactive material. The prepared 1-nm-thick PtNi nanozyme acted as a peroxidase, possessing higher catalytic activity than natural horseradish peroxidase (HRP) and other Pt-based mimic enzymes. Through the biotin-streptavidin specific interaction, streptavidin modified PtNi nanozyme was introduced into the dual-stranded DNA (dsDNA) formed by complementary DNA and biotinylated CAP aptamer. The PtNi nanozyme catalyzed 4-chloro-1-naphthol (4-CN) oxidation to generate insoluble precipitation on the electrode surface, resulting in an obvious photocurrent reduction. In the presence of CAP, the CAP aptamer was released from the electrode due to strong affinity with CAP, causing the decrease of catalytic precipitation and consequently the generation of a high photocurrent signal. On the basis of PtNi nanozyme signal amplification, the developed self-powered PEC aptasensor showed a wide linear range of 0.1 pM-100â¯nM with an ultralow detection limit of 26â¯fM for the determination of CAP. This work provides a feasible strategy for the design of high-activity nanozyme and self-powered PEC biosensor to achieve the ultrasensitive detection of target analyte.
Subject(s)
Anti-Bacterial Agents/analysis , Aptamers, Nucleotide/chemistry , Biosensing Techniques/instrumentation , Chloramphenicol/analysis , Nanowires/chemistry , Animals , Anti-Bacterial Agents/urine , Benzene/chemistry , Chloramphenicol/urine , Electrochemical Techniques/instrumentation , Equipment Design , Limit of Detection , Milk/chemistry , Nickel/chemistry , Platinum/chemistry , Rivers/chemistry , SwineABSTRACT
Although aptamer has been demonstrated as an important probe for antibiotic determination, the selective sensing of different antibiotics is still a challenge due to their structure similarities and wide folding degrees of aptamer. Herein, a field-effect transistor using MoS2 nanosheet as the channel and an aptamer DNA (APT) with its configuration shaped by a complementary strand DNA (CS) is employed for kanamycin (KAN) determination. This probe structure contributes to an enhanced selectivity and reliability with reduced device-to-device variations. This MoS2/APT/CS sensor shows time-dependent performance in antibiotic sensing. Prolonged detection time (20â¯s-300â¯s) leads to an enhanced sensitivity (1.85-4.43â¯M-1) and a lower limit of detection (1.06-0.66â¯nM), while a shorter detection time leads to a broader linear working range. A new sensing mechanism relying on charge release from probe is proposed, which is based on the "replacement reaction" between KAN and APT-CS. This sensor exhibits an extremely high selectivity (selectivity coefficient of 12.8) to kanamycin over other antibiotics including streptomycin, tobramycin, amoxicillin, ciprofloxacin and chloramphenicol. This work demonstrates the merits of probe engineering in label-free antibiotic detection with FET sensor, which presents significant promises in sensitive and selective chemical and biological sensing.
Subject(s)
Anti-Bacterial Agents/isolation & purification , Aptamers, Nucleotide/chemistry , Biosensing Techniques , Milk/chemistry , Animals , Anti-Bacterial Agents/chemistry , Cattle , Chloramphenicol/chemistry , Chloramphenicol/isolation & purification , DNA, Complementary/chemistry , Disulfides/chemistry , Gold/chemistry , Humans , Kanamycin/chemistry , Kanamycin/isolation & purification , Metal Nanoparticles/chemistry , Molybdenum/chemistry , Streptomycin/chemistry , Streptomycin/isolation & purification , Tobramycin/chemistry , Tobramycin/isolation & purificationABSTRACT
Intrinsic resistance in Pseudomonas aeruginosa, defined by chromosomally encoded low outer membrane permeability and constitutively over-expressed efflux pumps, is a major reason why the pathogen is refractory to many antibiotics. Herein, we report that heterodimeric rifampicin-tobramycin conjugates break this intrinsic resistance and sensitize multidrug and extensively drug-resistant P. aeruginosa to doxycycline and chloramphenicol in vitro and in vivo. Tetracyclines and chloramphenicol are model compounds for bacteriostatic effects, but when combined with rifampicin-tobramycin adjuvants, their effects became bactericidal at sub MIC levels. Potentiation of tetracyclines correlates with the SAR of this class of drugs and is consistent with outer membrane permeabilization and efflux pump inhibition. Overall, this strategy finds new uses for old drugs and presents an avenue to expand the therapeutic utility of legacy antibiotics to recalcitrant pathogens such as P. aeruginosa.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chloramphenicol/pharmacology , Doxycycline/pharmacology , Pseudomonas aeruginosa/drug effects , Rifampin/pharmacology , Tobramycin/pharmacology , Animals , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/toxicity , Bacterial Outer Membrane Proteins/metabolism , Drug Resistance, Multiple, Bacterial/drug effects , Drug Synergism , HEK293 Cells , Hep G2 Cells , Humans , Membrane Transport Proteins/metabolism , Microbial Sensitivity Tests , Molecular Structure , Moths , Rifampin/analogs & derivatives , Rifampin/chemical synthesis , Rifampin/toxicity , Swine , Tobramycin/analogs & derivatives , Tobramycin/chemical synthesis , Tobramycin/toxicitySubject(s)
Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Meningitis, Haemophilus/therapy , Pediatrics/history , Ampicillin/blood , Anti-Bacterial Agents/blood , Blood-Brain Barrier/drug effects , Child , Chloramphenicol , Drug Administration Schedule , Extracellular Fluid , Haemophilus influenzae type b , History, 20th Century , History, 21st Century , Humans , Microbial Sensitivity Tests , RecurrenceABSTRACT
Four binuclear phosphanesilver(I) dithiocarbamates, {cyclohexyl3PAg(S2CNRR')}2 for Râ¯=â¯R'â¯=â¯Et (1), CH2CH2 (2), CH2CH2OH (3) and Râ¯=â¯Me, R'â¯=â¯CH2CH2OH (4) have been synthesised and characterised by spectroscopy and crystallography, and feature tri-connective, µ2-bridging dithiocarbamate ligands and distorted tetrahedral geometries based on PS3 donor sets. The compounds were evaluated for anti-bacterial activity against a total of 12 clinically important pathogens. Based on minimum inhibitory concentration (MIC) and cell viability tests (human embryonic kidney cells, HEK 293), 1-4 are specifically active against Gram-positive bacteria while demonstrating low toxicity; 3 and 4 are active against methicillin resistant S. aureus (MRSA). Across the series, 4 was most effective and was more active than the standard anti-biotic chloramphenicol. Time kill assays reveal 1-4 to exhibit both time- and concentration-dependent pharmacokinetics against susceptible bacteria. Compound 4 demonstrates rapid (within 2â¯h) bactericidal activity at 1 and 2â¯×â¯MIC to reach a maximum decrease of 5.2â¯log10â¯CFU/mL against S. aureus (MRSA).
Subject(s)
Anti-Bacterial Agents , Coordination Complexes , Methicillin-Resistant Staphylococcus aureus/growth & development , Silver , Thiocarbamates , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Chloramphenicol/pharmacology , Coordination Complexes/chemical synthesis , Coordination Complexes/chemistry , Coordination Complexes/pharmacology , Drug Evaluation, Preclinical , Silver/chemistry , Silver/pharmacology , Thiocarbamates/chemical synthesis , Thiocarbamates/chemistry , Thiocarbamates/pharmacologyABSTRACT
Development of 1D nanostructures with novel morphology is a recent scientific attraction, so to say yielding unusual materials for advanced applications. In this work, we have prepared solution grown, single-pot 1D ZnWO4 nanowires (NWs) and the morphology is assessed for label-free but selective detection of chloramphenicol. This is the first report where, such structures are being investigated for this purpose. Transmission electron microscopy shows the presence of strands of ZnWO4 of about 20 nm in diameter. The formed NWs were highly dispersed in nature with uniform size and shape. X-ray diffraction analysis confirmed high purity of the designed NWs despite solution synthesis. X-ray photoelectron spectroscopy confirmed surface valence state of ZnWO4. Fourier transform infrared spectroscopy was employed for the ascription of functional groups, whereas, optical properties were investigated using photoluminescence. NWs were employed for the detection of a model antibiotic, chloramphenicol. The developed sensor exhibited excellent limit of detection, 0.32 µM and 100% specificity as compared to its structural and functional analogues such as thiamphenicol and clindamycin. This work can broaden new opportunities for the researchers to explore unconventional nanomaterials bearing unique morphologies and quantum phenomenon for the label-free detection of other bioanalytes.